Advanced search
Publication Cover
Infectious Diseases Volume 52, 2020 - Issue 9
Submit an article Journal homepage
650
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Tocilizumab for COVID-19: a real ‘miracle drug’?

Sundus NasimDow Medical College, Dow University of Health Sciences, Karachi, Pakistan; Correspondence[email protected]
,
Shariq Haider HashmiNYU Grossman School of Medicine, New York City, NY, USA
,
Dua AzimDow Medical College, Dow University of Health Sciences, Karachi, Pakistan;
,
Sohail KumarDow Medical College, Dow University of Health Sciences, Karachi, Pakistan; ORCID Iconhttp://orcid.org/0000-0002-7947-4553
ORCID Icon &
Jasia NasimDow Medical College, Dow University of Health Sciences, Karachi, Pakistan;
Pages 681-682 | Received 29 May 2020, Accepted 04 Jun 2020, Published online: 17 Jun 2020

References

  • Hou W, Zhang W, Jin R, et al. Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study. Infect Dis. 2020;52:498–505.
  • Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18(1):164.
  • Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
  • Luo W, Yu H, Gou J, et al. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Preprints. 2020;2020020407.
  • Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970–10975.
  • Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92:814–818.
  • Alzghari SK, Acuña VS. Supportive treatment with tocilizumab for COVID-19: a systematic review. J Clin Virol. 2020;127:104380.
  • Strangfeld A, Richter A, Siegmund B, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2017;76(3):504–510.
  • Lin L, Jiang X, Zhang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020;69(6):997–1001.
  • Morrison AR, Johnson JM, Ramesh M, et al. Letter to the Editor: acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab. J Med Virol. 2020. DOI:10.1002/jmv.25907

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.